Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study.

ABSTRACT:

Background

Influenza causes substantial morbidity and mortality despite available treatments. Anecdotal reports suggest that plasma with high antibody titres to influenza might be of benefit in the treatment of severe influenza.

Methods

In this randomised, open-label, multicentre, phase 2 trial, 29 academic medical centres in the USA assessed the safety and efficacy of anti-influenza plasma with haemagglutination inhibition antibody titres of 1:80 or more to the infecting strain. Hospitalised children and adults (including pregnant women) with severe influenza A or B (defined as the presence of hypoxia or tachypnoea) were randomly assigned to receive either two units (or paediatric equivalent) of anti-influenza plasma plus standard care, versus standard care alone, and were

SUBMITTER: Beigel JH 

PROVIDER: S-EPMC5828518 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature